This MAPP provides recommendations to CMC reviewers within FDA’s Office of Pharmaceutical Science on the appropriate use of ICH recommendations for evaluating acceptance criteria for residual solvents in drug substances and products proposed in new drug applications, abbreviated new drug applications, biologics license applications and related supplements.

To read more, click here.